Toronto, Ontario--(Newsfile Corp. - September 23, 2025) - Neural Therapeutics Inc. (CSE: NURL) (FSE: HANF) ("Neural" or the "Company"), an ethnobotanical drug discovery company focused on developing therapeutic solutions for substance use disorders, together with CWE European Holdings Inc. ("CWE"), operating as Hanf.com, one of Germany's leading CBD retailers, is pleased to announce the opening of its 17th retail location in the City of Freising, Bavaria. As disclosed in Neural's press release dated August 13, 2025, Neural owns a 30.75% interest in CWE with an option to acquire the remaining 69.25% upon satisfaction of certain conditions.
Freising, a vibrant university city of more than 50,000 residents, is strategically located near Munich International Airport and serves as a key hub for the greater Munich metropolitan area. As part of Hanf.com's growth strategy in Bavaria, the new store will be company-operated rather than franchised, ensuring consistent customer experience and maintaining the brand's high standards.
"We are excited to bring the Hanf.com experience to Freising - a city with a rich history, strong community values, a large student population and a forward-looking spirit," said Alex Cerveny, COO of Hanf.com. "This new location not only expands our presence in Bavaria but also strengthens our reach into Munich and its surrounding suburbs, resulting in greater customer access to Hanf.com's trusted products and expertise. Furthermore, our established infrastructure in the region allows for greater financial efficiencies, thereby adding higher-margin revenue to Hanf.com's strong fundamentals and a track record of growth."
The opening of the Freising store marks another important step in Hanf.com's ongoing expansion strategy, solidifying its position as a market leader in Germany's fast-growing CBD retail sector. Information about Hanf.com retail footprint across Germany can be found at https://hanf.com/info/filialfinder/.
About Neural Therapeutics
Neural Therapeutics is a leader in ethnobotanical drug discovery, focusing on the development of therapeutic drugs for mental illnesses related to substance use disorders, including alcohol and opioid dependence. The Company's innovative approach to drug development involves the strategic use of sub-hallucinogenic doses of mescaline extract, enhancing safety and scalability while maintaining therapeutic efficacy.
On May 26, 2025, Neural entered into a Strategic Investment and Option Agreement with CWE European Holdings Inc., a leading CBD hemp retailer in Germany operating under the brand Hanf.com, to acquire up to 100% of CWE through a multi-stage transaction. The transaction is expected to expand Neural's commercial footprint in Europe while maintaining its core commitment to drug discovery and mental health innovation.
For further inquiries, please contact:
Neural Therapeutics Inc.
Ian Campbell, CEO
E: icampbell@neuraltherapeutics.ca
T: +1 (647) 697-NURL (6875)
Marc Lakmaaker
E: mlakmaaker@gmail.com
T: +1.647.289.6640
CAUTIONARY DISCLAIMER STATEMENT
No securities regulatory authority has reviewed or accepted responsibility for the adequacy or accuracy of the contents of this news release. This news release contains forward-looking statements ("FLS") relating to the opening of new retail locations by CWE (operating as Hanf.com), the growth and performance of Hanf.com's business, Neural's indirect exposure to such growth through its investment in CWE, and Neural's continued focus on ethnobotanical drug discovery. FLS may also include statements regarding potential synergies arising from Neurals investment in CWE, expected consumer reception of Hanf.com's products and projections about European market demand for hemp and CBD-related goods. FLS are often identified by words such as "will", "may", "should", "anticipate", "expect", "plan" and similar expressions. These statements are not statements of historical fact, but rather predictions about future events and are inherently subject to risks and uncertainties. Actual results and future events could differ materially from those anticipated in such statements. Readers are cautioned should not to place undue reliance on any forward-looking information. Although management believes such information to be reasonable at the time of preparation, actual outcomes may differ significantly. FLS contained in this news release are expressly qualified by this cautionary statement. Neural expressly disclaims any intention or obligation to update or revise such statements. A description of additional risk factors that may cause actual results to differ materially from FLS in Neural's disclosure documents posted on www.sedarplus.ca.
The securities of Neural have not been registered under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act"), or applicable state securities laws. The securities may not be offered or sold to, or for the account or benefit of, persons in the United States or "U.S. Persons" (as defined in Regulation S under the U.S. Securities Act), unless registered or exempt from registration under the U.S. Securities Act and applicable state securities laws. This press release does not constitute an offer to sell or the solicitation of an offer to buy Neural's securities in the United States or any other jurisdiction where such an offer or sale would be unlawful.
Neither CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/267603
SOURCE: Neural Therapeutics Inc.
